Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorderActive, not recruitingPhase 12026-07-31NCT02627443

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Mayo Clinic Hospital in ArizonaPhoenixUnited States120
Mayo Clinic in ArizonaScottsdaleUnited States191
Mayo Clinic in FloridaJacksonvilleUnited States224
Mayo Clinic in RochesterRochesterUnited States687
Rutgers Cancer Institute of New JerseyNew BrunswickUnited States223
Thomas Jefferson University HospitalPhiladelphiaUnited States271
UCHealth University of Colorado HospitalAuroraUnited States172
UF Health Cancer Institute - GainesvilleGainesvilleUnited States153
University of Kentucky/Markey Cancer CenterLexingtonUnited States240
University of Virginia Cancer CenterCharlottesvilleUnited States206
UPMC Hillman Cancer CenterPittsburghUnited States330
Washington University School of MedicineSt LouisUnited States895
Wayne State University/Karmanos Cancer InstituteDetroitUnited States196
Weisberg Cancer Treatment CenterFarmington HillsUnited States135